MCP Waters-The Science of What's Possible
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on April 1, 2002.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M100031-MCP200v1
1/4/269    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Glossary
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Celis, J. E.
Right arrow Articles by Gromova, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Celis, J. E.
Right arrow Articles by Gromova, I.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on November 23, 2001
Revised on March 21, 2002
Accepted on March 21, 2002

Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas

Julio E. Celis, Pamela Celis, Hildur Palsdottir, Morten Ostergaard, Pavel Gromov, Hanne Primdahl, Torben F. Orntoft, Hans Wolf, Ariana Celis, and Irina Gromova

Institute of Cancer Biology &, The Danish Cancer Society, Copenhagen 2100

Corresponding Author: jec{at}cancer.dk

Proteomics and immunohistochemistry were used to reveal tumor heterogeneity among urothelial papillomas (UPs) with the long-term goal of predicting their biological potential in terms of outcome. First, we identified proteins that were deregulated in invasive fresh lesions as compared to normal urothelium. Twenty-two major proteins showing variations of two-fold or more in at least one third of the invasive lesions were selected. A panel consisting of antibodies against CKs 5, 13, 18 and 20 and markers of squamous metaplasia (CKs 7, 8 and 14) was used to probe normal urothelium and 30 UPs collected during a period of five years. Four UPs showed a normal staining phenotype, while the rest could be grouped in 5 major types, that with the exception of type 1, shared aberrant staining with the CK20 antibody. UPs exhibited only one major type of heterogeneity that in most cases included variants. Type 1 heterogeneity (n=4) showed preferred staining of the umbrella cells with the CK8 antibody. Type 2 (n=11) was typified by the staining of the basal and intermediate layers with the CK20 antibody. Type 3 (n=7) was characterized by the predominant staining of the basal cell layer with the CK5 antibody. Type 4 (n=1) showed areas of CK7 negative cells, while type 5 (n=3) showed loss of staining of the basal cells with the CK20 antibody. 29% of the patients experienced recurrences but none progressed to invasive disease. The number of recurrences was higher in the case of types 3 and 5 (4/7 and 2/3, respectively), and all recurrent type 3 lesions progressed to a higher degree of dedifferentiation. Even though a long-term prospective study involving a larger sample size will be required to assess the biological potential of these lesions, we believe that this approach will prove instrumental for revealing cancer heterogeneity.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. ProteomicsHome page
J. E. Celis, P. Gromov, J. M. A. Moreira, T. Cabezon, E. Friis, I. M. M. Vejborg, G. Proess, F. Rank, and I. Gromova
Apocrine Cysts of the Breast: Biomarkers, Origin, Enlargement, and Relation with Cancer Phenotype
Mol. Cell. Proteomics, March 1, 2006; 5(3): 462 - 483.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Melle, G. Ernst, B. Schimmel, A. Bleul, S. Koscielny, A. Wiesner, R. Bogumil, U. Moller, D. Osterloh, K.-J. Halbhuber, et al.
A Technical Triade for Proteomic Identification and Characterization of Cancer Biomarkers
Cancer Res., June 15, 2004; 64(12): 4099 - 4104.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
J. M. A. Moreira, P. Gromov, and J. E. Celis
Expression of the Tumor Suppressor Protein 14-3-3{sigma} Is Down-regulated in Invasive Transitional Cell Carcinomas of the Urinary Bladder Undergoing Epithelial-to-Mesenchymal Transition
Mol. Cell. Proteomics, April 1, 2004; 3(4): 410 - 419.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
J. E. Celis, P. Gromov, I. Gromova, J. M. A. Moreira, T. Cabezon, N. Ambartsumian, M. Grigorian, E. Lukanidin, P. thor Straten, P. Guldberg, et al.
Integrating Proteomic and Functional Genomic Technologies in Discovery-driven Translational Breast Cancer Research
Mol. Cell. Proteomics, June 1, 2003; 2(6): 369 - 377.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
P. Gromov, G. L. Skovgaard, H. Palsdottir, I. Gromova, M. Ostergaard, and J. E. Celis
Protein Profiling of the Human Epidermis from the Elderly Reveals Up-regulation of a Signature of Interferon-{gamma}-induced Polypeptides That Includes Manganese-superoxide Dismutase and the p85{beta} Subunit of Phosphatidylinositol 3-Kinase
Mol. Cell. Proteomics, February 1, 2003; 2(2): 70 - 84.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.